AMIGO2 and pancreatic adenocarcinoma: A pan-cancer survival comparison using TCGA data further demonstrated that the prognostic impact of AMIGO2 was predominantly observed in PAAD (HR = 2.21, p = 0.00045), whereas no significant associations were detected in COAD, STAD, BRCA, or LUAD (Supplementary Figure S1 and Table S1).